Pharma Focus Asia

Hovione Invests US$170 million to Expand Global Capacity


Hovione plans to expand its  new capacity and capabilities in Portugal, Ireland, and New Jersey with an investment of US$170 million.


This expansion of industrial facilities across the world will support its ambitious growth objectivesto meet customer needs.

The expansion will support the growing demand for pharma custom development and manufacturing service business followed by integrated and differentiated services in drug substance manufacturing, particle engineering and drug product manufacturing.

Expansion of Units in New Jersey, Ireland and Portugal
In USA, the new state-of-the-art2900m2 campus will be located adjacent to current facility in East Windsor, New Jersey. The new building will additional commercial spray drying capacity online by 2023.

The expansion will allow both the current and new customers of US-based manufacturing through their development cycles all the way to commercial.

In Ireland, the facility at will be upgraded to increase the production of Highly Potent Active Pharmaceutical Ingredients (HPAPI). In addition, with the addition of unique technologiesthe site supports huge customer projects finding a new home by connecting to the existing infrastructure and equipment.

In Portugal, the facility is designed due to the increase in chemical synthesis capacity for High Potency Active Pharmaceutical Ingredients (HPAPI).

The new expansion will creat more than 300 new jobs globally.


BudgetUS$170 million
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference